PKCθ Antibody, anti-human, REAfinity™
Synonyms: PKCtheta
RECOMBINANT
Clone:
REA588 | 27/PKCq
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for PKCθ Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
PE
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-109-230, 130-109-308
Description:
Human peripheral blood mononuclear cells (PBMCs) were either left unstimulated (left peak) or stimulated with 10 µM PMA at 37 °C for 24 hours. Cells were then fixed and permeabilized using the Cell Signaling Buffer Set A and stained with Anti-PKCθ antibodies. CD3+ cells were pregated for the analysis. Flow cytometry was performed using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application image
Specifications for PKCθ Antibody, anti-human, REAfinity™
Overview

Clone REA588 recognizes the human PKCθ antigen, which is a member of the protein kinase C (PKC) family of homologous serine/threonine protein kinases that phosphorylate the OH group of serine or threonine. PKCs play a role in the carcinogenesis and maintenance of malignant phenotype. PKCθ transcripts are expressed in hematopoietic tissues and cell lines, including T cells and thymocytes.

Additional information: Clone REA588 displays negligible binding to Fc receptors.

Alternative names

PKCtheta

Detailed product information

Technical specifications

Clone
REA588
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
PKCθ
Molecular mass of antigen [kDa]
82
Distribution of antigen
T cells, thymocytes
Entrez Gene ID
RRID
AB_2653215, AB_2653216, AB_2653214, AB_2653213

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for PKCθ Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for PKCθ Antibody, anti-human, REAfinity™
Publications
  1. Koivunen, J. et al. (2006) Protein kinase C (PKC) family in cancer progression. Cancer Lett. 235 (1): 1-10
  2. Nishizuka, Y. (1988) The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334 (6184): 661-665